EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol

Taku Fujimura iD, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi und 5 weitere

Experimental Dermatology · 2024-01 · 33 (1)

DOI: 10.1111/exd.14976 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Experimental Dermatology, online erschienen am 09.11.2023. Verfasst von Taku Fujimura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hemangiosarcoma, Skin Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Renascience Inc., Tokyo, Japan..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous angiosarcoma (CAS) is an endothelial cell‐derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial, and there is no standard therapy for taxane‐resistant CAS. Plasminogen activator inhibitor‐1 (PAI‐1) is associated with poor clinical outcomes, and elevated levels of PAI‐1 in both tissue and serum are correlated with poor response to therapy in various cancers, including skin cancers. Since PAI‐1 protects endothelial cells from Fas ligand‐mediated apoptosis, PAI‐1 inhibition might induce apoptosis of endothelial cell‐derived tumours such as CAS. This is a single‐arm, open‐label, multi‐institutional, Phase 2 clinical trial to assess the efficacy and safety of PTX in combination with TM5614 (PAI‐1 inhibitor) in patients with PTX‐resistant CAS. PTX will be administered for 28 weeks, with oral administration of TM5614. The primary endpoint of this study will be the overall response rate (ORR) at 28 weeks after starting treatment (central image evaluation). The secondary endpoint will include the ORR at 28 weeks after starting treatment (investigator evaluation), ORR at 8 weeks and 16 weeks after initiation of treatment (central and investigator evaluation), progression‐free survival, overall survival, disease control rate and safety profiles. Assuming the null hypothesis of a response rate of 13.6% and an alternative hypothesis of 45%, a minimum of 15 patients are required to achieve a two‐sided, Type I error of 5% and power of 70% based on the exact binomial distribution. Data quality control will be conducted by a combination of centralized (remote) and on‐site monitoring. This study will contribute to the development of novel combination therapy for PTX‐resistant CAS patients, which remains an unmet clinical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsHemangiosarcomaSkin NeoplasmsHumansClinical Trials, Phase II as TopicEndothelial CellsPaclitaxelPlasminogen Activator Inhibitor 1Multicenter Studies as Topic

Stichwörter der Autor:innen

PAI-1PAI-1 inhibitorsPTXclinical trialstaxane-resistant CAS

Substanzen

PaclitaxelPlasminogen Activator Inhibitor 1

Autor:innen und Institutionen

  • Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
  • Department of Dermato-Oncology/Dermatology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
  • Department of Dermatology, Jichi Medical University Saitama Medical Center, Shimotsuke, Japan.
  • Department of Dermatology, Ehime University, Matsuyama, Japan.

ORCID-Profile: Taku Fujimura

Förderung

  • Renascience Inc., Tokyo, Japan.

Zitieren

APA

Fujimura, T., Yoshino, K., Nakamura, M., Kato, H., Ito, T., Maekawa, T., Fujisawa, Y., Matsushita, S., Amagai, R., Yamazaki, E., Takahashi, M., Tamabuchi, E., Hashimoto, A., Kambayashi, Y., Yamazaki, N., Miyata, T., & Asano, Y. (2024). Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol. Experimental Dermatology, 33(1). https://doi.org/10.1111/exd.14976

Vancouver

Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, et al. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol. Experimental Dermatology. 2024;33(1). doi:10.1111/exd.14976

BibTeX
@article{Fujimura2024,
  author = {Fujimura, Taku and Yoshino, Koji and Nakamura, Motoki and Kato, Hiroshi and Ito, Takamichi and Maekawa, Takeo and Fujisawa, Yasuhiro and Matsushita, Shigeto and Amagai, Ryo and Yamazaki, Emi and Takahashi, Manami and Tamabuchi, Erika and Hashimoto, Akira and Kambayashi, Yumi and Yamazaki, Naoya and Miyata, Toshio and Asano, Yoshihide},
  title = {Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol},
  journal = {Experimental Dermatology},
  year = {2024},
  volume = {33},
  number = {1},
  doi = {10.1111/exd.14976}
}
Kostenlos starten →